Interestingly, previous studies have shown that elevated PD-L1 expression in HCC supports the development of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, and the expression levels of CD8+ T cells and PD-L1 can be used as benchmarks to evaluate new therapies in HCC [34]. This evidence concerns the gene CD8A and hepatocellular carcinoma.